Skip to Main Content

Rise and shine, everyone, another busy day is on the way. The Pharmalot campus, for instance, is already bustling as our short person has darted out the door for the local schoolhouse and the official mascots are hungrily sniffing about the grounds for wild game. As for us, the coffee kettle is fired up so we can brew delicious cups of stimulation. So time to dig into the tidbits below and get your game going. Have a wonderful day and do keep in touch …

The Food and Drug Administration approved a three-in-one lung inhaler from GlaxoSmithKline (GSK) for treating chronic lung disease, Reuters tells us. Trelegy Ellipta, which is the first such treatment for chronic obstructive pulmonary disease, is a key new product for the drug maker, which is scrambling to keep its lead in respiratory medicines despite falling sales of its older Advair drug.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!